Japanese Journal of Cancer and Chemotherapy最新文献_第3页

[Two Patients with Ciliated Muconodular Papillary Tumor Whose Preoperative Diagnosis Was Difficult]. [2例术前诊断困难的纤毛状粘液结节乳头状瘤]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-08-01

Hiroshi Nishimura, Takashi Nojiri, Masahiko Higashiyama

{"title":"[Two Patients with Ciliated Muconodular Papillary Tumor Whose Preoperative Diagnosis Was Difficult].","authors":"Hiroshi Nishimura, Takashi Nojiri, Masahiko Higashiyama","doi":"","DOIUrl":"","url":null,"abstract":"Ciliated muconodular papillary tumors (CMPT) are rare lung tumors characterized by the papillary proliferation of ciliated and goblet cells. We report 2 patients with CMPT following surgical resection of pulmonary nodules who showed increased shadowing after malignant tumor treatment. The first patient, a male in his 70s, was referred for an enlarging nodule in the right middle lobe of the lung detected during a postoperative follow-up for sigmoid colon cancer. Contrast-enhanced chest computed tomography (CT) revealed an 11 mm irregular nodule in the right middle lobe. Wedge resection was performed using video-assisted thoracic surgery. The intraoperative rapid diagnosis was adenocarcinoma, but the permanent specimen was diagnosed as CMPT. The second patient, a woman in her 80s with a history of left-sided breast cancer, was referred for evaluation of a nodule in the left upper lobe of the lung detected on plain CT. A plain chest CT revealed a 10 mm nodule in the left upper lobe. A segmentectomy of the upper division of the left lung was performed. Intraoperative rapid diagnosis revealed that the mass was of unknown nature, but the permanent specimen was diagnosed with CMPT. CMPT is difficult to diagnose preoperatively and intraoperatively. In patients with malignant tumors, definitive surgical resection is necessary for differential diagnosis.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 8","pages":"517-520"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Perioperative Immune Checkpoint Inhibitor Therapy for Non-Small Cell Lung Cancer]. [非小细胞肺癌围手术期免疫检查点抑制剂治疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-08-01

Suguru Matsuda, Hirotsugu Kenmotsu

引用次数: 0

[Perioperative Breast Cancer Treatment with Immune Checkpoint Inhibitors-Current Status and Future Perspectives]. [免疫检查点抑制剂治疗围手术期乳腺癌-现状和未来展望]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-08-01

Kazuki Nozawa, Hiroji Iwata

{"title":"[Perioperative Breast Cancer Treatment with Immune Checkpoint Inhibitors-Current Status and Future Perspectives].","authors":"Kazuki Nozawa, Hiroji Iwata","doi":"","DOIUrl":"","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer immunotherapy and have become standard treatment for several solid tumors. Although breast cancer has traditionally been considered a tumor with low immunogenicity, the clinical utility of ICIs has been demonstrated, particularly in triple-negative breast cancer (TNBC). In the perioperative setting for TNBC, the KEYNOTE-522 trial showed that the addition of pembrolizumab to chemotherapy significantly improved pathological complete response (pCR) rates, event-free survival (EFS), and overall survival (OS), establishing a new standard of care. For hormone receptor-positive (HR+)/HER2-negative breast cancer, the KEYNOTE-756 and CheckMate 7FL trials have suggested the potential efficacy of perioperative ICIs, with particularly promising results in patient subgroups with low estrogen receptor (ER) expression and PD-L1 positivity. However, several challenges remain, including the establishment of predictive biomarkers, management of immune-related adverse events, and overcoming resistance mechanisms. Future directions include the optimization of biomarker-guided patient selection, the development of novel combination therapies with antibody-drug conjugates (ADCs) and PARP inhibitors, and the clinical development of next-generation immunotherapies such as CAR-T cell therapy and tumor-infiltrating lymphocyte (TIL) therapy, with the goal of extending the benefits of immunotherapy to a broader population of breast cancer patients.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 8","pages":"502-506"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Evolving Role of Perioperative Immune Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer]. [围手术期免疫检查点抑制剂在肌肉浸润性膀胱癌中的作用]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-08-01

Takashi Kawahara, Hiroyuki Nishiyama

{"title":"[Evolving Role of Perioperative Immune Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer].","authors":"Takashi Kawahara, Hiroyuki Nishiyama","doi":"","DOIUrl":"","url":null,"abstract":"Muscle-invasive bladder cancer (MIBC) is associated with a high risk of recurrence and metastasis, and its prognosis remains unsatisfactory despite radical cystectomy. Perioperative cisplatin-based chemotherapy has long been the standard approach; however, its efficacy is limited, and a substantial proportion of patients are ineligible for cisplatin. In recent years, the introduction of immune checkpoint inhibitors (ICIs) has significantly transformed the treatment landscape of bladder cancer. In the neoadjuvant setting, ICIs alone or in combination with chemotherapy have demonstrated promising pathological complete response rates, suggesting potential benefits even for patients ineligible for cisplatin-based regimens. In the adjuvant setting, randomized trials have shown improvements in disease-free survival, although the benefits are not consistent. Emerging evidence highlights the potential role of circulating tumor DNA as a biomarker to identify patients who are more likely to benefit from adjuvant immunotherapy. Furthermore, recent studies of perioperative combination strategies, including ICIs with chemotherapy or antibody-drug conjugates, have demonstrated encouraging survival outcomes. These advances indicate a shift toward more personalized and biomarker-driven treatment approaches in MIBC. This article provides an overview of current developments in perioperative ICI-based therapies for MIBC.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 8","pages":"507-511"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Isolated ACTH Deficiency after Conversion Surgery Following Gemcitabine, Cisplatin, and Pembrolizumab for Distal Cholangiocarcinoma]. [吉西他滨、顺铂和派姆单抗治疗远端胆管癌转化手术后孤立性ACTH缺乏1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-08-01

Shota Hotchi, Takayuki Miura, Shuichi Aoki, Hideaki Sato, Mitsuhiro Shimura, Masahiro Iseki, Daisuke Douchi, Shimpei Maeda, Masaharu Ishida, Masamichi Mizuma, Takashi Kamei, Michiaki Unno

{"title":"[A Case of Isolated ACTH Deficiency after Conversion Surgery Following Gemcitabine, Cisplatin, and Pembrolizumab for Distal Cholangiocarcinoma].","authors":"Shota Hotchi, Takayuki Miura, Shuichi Aoki, Hideaki Sato, Mitsuhiro Shimura, Masahiro Iseki, Daisuke Douchi, Shimpei Maeda, Masaharu Ishida, Masamichi Mizuma, Takashi Kamei, Michiaki Unno","doi":"","DOIUrl":"","url":null,"abstract":"We report the case of a 69-year-old man who was initially diagnosed with resectable distal cholangiocarcinoma, for which radical resection was planned. However, the disease was reclassified as an unresectable distal cholangiocarcinoma because peritoneal cytology was positive. After 8 courses of gemcitabine, cisplatin, and pembrolizumab (GCP) therapy, pancreaticoduodenectomy was performed as a conversion surgery because the peritoneal cytology was negative. During surgery, no non-curative factors were identified, and an R0 resection was achieved. On postoperative day 14, the patient developed a fever suspected of cholangitis, and the hyponatremia that appeared on day 20 became prolonged. Suspecting adrenal insufficiency, hydrocortisone replacement was initiated on day 27. The serum sodium levels gradually increased, which allowed tapering of the hydrocortisone dose. As only ACTH levels decreased among the anterior pituitary hormones examined, a diagnosis of isolated ACTH deficiency was made. Ten months postoperatively, the patient received S-1 as adjuvant chemotherapy, continued oral hydrocortisone, and is doing well without adverse events. Clinicians should be aware of irAEs during the perioperative period after ICI therapy. Serious complications can be prevented through multidisciplinary collaboration.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 8","pages":"533-535"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report]. 同步滤泡性淋巴瘤和肺腺癌1例报告。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Masahiro Manabe, Yoshiaki Matsuura, Daisuke Aohara, Daiki Mukai, Satoru Nanno, Ki-Ryang Koh

引用次数: 0

[A Case of Advanced Gastric Cancer That Had Been Completely Cured by Single Dose of wPTX plus RAM]. [单剂wPTX加RAM完全治愈晚期胃癌1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Kouichirou Tahara, Kazuaki Hiroishi, Iori Kai

{"title":"[A Case of Advanced Gastric Cancer That Had Been Completely Cured by Single Dose of wPTX plus RAM].","authors":"Kouichirou Tahara, Kazuaki Hiroishi, Iori Kai","doi":"","DOIUrl":"","url":null,"abstract":"A 72-year-old man was diagnosed with advanced gastric cancer with severe gastric stenosis, lymph node metastasis, and portal vein invasion. He underwent ileo-gastrostomy, then received chemotherapy using 4 cycles of S-1 and 2 cycles of SOX. The response to this therapy was judged PD; thus, second-line therapy of wPTX + RAM was introduced, although icterus and ascites were recognized then. After a single injection of wPTX + RAM, G4 neutropenia, anorexia, and severe ascites were observed. Thus, the chemotherapy was discontinued. At that point, he had been diagnosed with severe liver cirrhosis, and internal treatment was introduced. Six weeks after the last injection of anti-cancer drugs, CT revealed tumor shrinkage and highly reduced serum CEA, although ascites increased. Subsequently, ascites and general condition gradually recovered without anti-cancer therapy. One year after the last injection of anti-cancer drugs, the primary tumor, lymph node metastasis, and portal vein invasion were not observed on CT and endoscopy, and the patient was judged cCR. This rare case demonstrated prolonged effect of wPTX + RAM that caused the depression of liver metabolism. Therefore, anti-cancer immune response has been induced by an unknown mechanism.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"468-470"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Cancer Early Detection by cfDNA Analyses]. [cfDNA分析的癌症早期检测]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Chikashi Ishioka

{"title":"[Cancer Early Detection by cfDNA Analyses].","authors":"Chikashi Ishioka","doi":"","DOIUrl":"","url":null,"abstract":"The analysis of cell-free DNA (cfDNA) in blood is expected to serve as a new diagnostic method for early cancer detection and treatment monitoring by examining trace amounts of ctDNA derived from cancer cells. In cancer patients, ctDNA circulates in the bloodstream, and thanks to technological innovations in next-generation sequencing (NGS) and the analysis of fragmented DNA at low levels, it is now possible to non-invasively detect the presence and type of cancer. Multi-cancer early detection (MCED) is a method for detecting cancer early and identifying its specific type by analyzing cfDNA fragment characteristics, ctDNA somatic variants, and DNA methylation status; some MCED tests are already commercially available. However, when used as a standalone test, MCED faces challenges in early detection reliability and the risk of overdiagnosis, necessitating improvements in sensitivity and specificity, as well as clinical efficacy evidence. For this reason, MCED is currently positioned to complement existing screening methods. Furthermore, in addition to analyzing DNA fragment characteristics and methylation, machine learning is expected to enable more accurate detection. However, challenges remain, such as improving sensitivity in clinical stage Ⅰ and reducing false positives, making further research progress essential. Nevertheless, MCED holds great potential for personalized cancer prevention. This review discusses early cancer diagnosis using cfDNA analysis and the technological advancements in this field.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"429-434"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events]. [替索妥单抗维多汀肿瘤-眼科合作的建立和眼部不良事件的初步经验]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Shogen Boku, Kaoru Araki-Sasaki, Keiko Sakaguchi, Hitomi Sakaguchi, Ryohei Fujii, Atsuko Ishimoto, Masato Kita, Masafumi Kanai, Takayasu Kurata

{"title":"[Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events].","authors":"Shogen Boku, Kaoru Araki-Sasaki, Keiko Sakaguchi, Hitomi Sakaguchi, Ryohei Fujii, Atsuko Ishimoto, Masato Kita, Masafumi Kanai, Takayasu Kurata","doi":"","DOIUrl":"","url":null,"abstract":"Background: Tisotumab vedotin (TV), an antibody-drug conjugate targeting tissue factor (TF), was approved in Japan in 2025 for the treatment of recurrent/metastatic cervical cancer. As TF is also expressed on the ocular surface, TV frequently causes ocular adverse events (OAEs), necessitating strict management. This paper reports on the established'onco-ophthalmology'collaboration system developed to manage these risks.Methods: A multidisciplinary protocol involving medical oncologists, ophthalmologists, pharmacists, and nurses was implemented. Key components included pre-treatment ophthalmic assessment, pharmacist-led guidance on prophylactic eye drops, cooling during treatment, and a rapid referral system upon symptom onset.Results: Between June and October 2025, 5 patients received TV therapy. One case (20%) developed Grade 2 pseudomembranous conjunctivitis. Immediate ophthalmic evaluation revealed neutrophilic infiltration without infectious findings on smear examination. Symptoms resolved within 7 days of steroid treatment.Conclusion: Whilst preventative measures are crucial, ocular complications remain possible. This case demonstrates that early diagnosis and effective management are achievable through the onco-ophthalmology liaison system, ensuring the safe continuation of TV therapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"459-461"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors]. [靶向kras突变型癌症- RAS抑制剂耐药的治疗策略和机制]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Hiromichi Ebi

引用次数: 0